CEO: Peter Heifetz.

Revenue: Pre-revenue.

No. of local employees: Two full-time, supplemented by consultants and advisers.

Investors: Self-funded.

Headquarters: San Diego.

Year founded: 2011.

Company description: Preclinical stage biopharmaceutical company developing recombinant thioredoxin for the treatment of cystic fibrosis and other obstructive pulmonary diseases.

Key factors for success: Backing by National Institutes of Health. Has assembled ‘world-class’ team of experts to advise on research, development, manufacturing and financing.

A monetary ripple in the funding waters could bring a wave of change to OrPro Therapeutics Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99